Remove Assay Development Remove Drugs Remove Small Molecule
article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96
article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New image-based cellular profiling tool peers deeply into metabolic biology

Broad Institute

LipocyteProfiler builds on the concept of image-based profiling that was first introduced in the context of morphology mapping by Cell Painting, a high-content imaging assay developed by Broad institute scientist and Imaging Platform senior director Anne Carpenter.

article thumbnail

Six Factors for Biotech Companies to Consider When Choosing Next-Generation Contract GMP/CMC Laboratories

PPD

With the depth of knowledge to support all types of pharmaceutical products across all phases of development, we provide services ranging from end-to-end assay development to platform expansion, designed with the client’s timeline and budget in mind. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.

article thumbnail

Biophysics

Sygnature Discovery

At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

article thumbnail

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

Sygnature Discovery

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The two companies have collaborated in cardiovascular drug discovery since March 2021.